Geoffrey Shapiro, MD
Enriched profileSenior Vice President, Developmental Therapeutics, Dana-Farber Cancer Institute · Dana-Farber Cancer Institute
Geoffrey Shapiro is Senior Vice President, Developmental Therapeutics, Dana-Farber Cancer Institute at Dana-Farber Cancer Institute. OpenAlex indexes 2,055 publications with 58,071 citations (h-index 116); ClinicalTrials.gov lists 25 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Medical Oncology profiles in the findmyKOL directory. Clarivate lists Geoffrey Shapiro as a Highly Cited Researcher (Clinical Medicine, 2019-2022).
Data verified 25 Aug 2026
Overview
Updated 16 Oct 2026
Geoffrey Shapiro, MD PHD, is Senior Vice President, Developmental Therapeutics, Dana-Farber Cancer Institute. The public record shows 2,055 publications with 58,071 citations (h-index 116), centered on Lung Cancer Treatments and Mutations, Cancer Genomics and Diagnostics, PARP inhibition in cancer therapy. It also documents an investigator role on 25 registered clinical trials, industry payments reported by 6 companies, 11 NIH-funded awards (1997–2026).
- Most recent indexed publication: 2026 · Journal of clinical oncology
- Top research focus: Lung Cancer Treatments and Mutations
- 25 registered trials on ClinicalTrials.gov
- Open Payments reporting from 6 companies
Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 71 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 392.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 16 Oct 2026
Listed as an investigator on 25 registered studies on ClinicalTrials.gov. The most recent:
- Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes
Sponsor: National Cancer Institute (NCI)
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Sponsor: National Cancer Institute (NCI)
- Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial
Sponsor: National Cancer Institute (NCI)
Industry payments
Updated 16 Oct 2026
6 companies reported payments to CMS in program years 2021–2024. These are public disclosures, not judgments. The latest:
- EMD Serono Research & Development Institute, Inc.Program year20241 payment
- E.R. Squibb & Sons, L.L.C.Program year20241 payment
- Bayer HealthCare Pharmaceuticals Inc.Program year20214 payments
Medicare prescribing footprint (2021)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
100%Short-acting sulfonamides100%Sulfamethoxazole-Trimethoprim100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 16 Oct 2026
11 NIH research awards on record, funded 1997–2026 per NIH RePORTER. The latest:
- Dana Farber/Harvard Cancer Center Specialized Program of Research Excellence in Breast Cancer
Dana-Farber Cancer Inst
FY2026$2,525,262P50CA168504 - Extension of the Dana Farber Harvard Cancer Center Consortium for the ETCTN
Dana-Farber Cancer Inst
FY2026$2,272,446UM1CA186709 - Macrophage-directed strategies for BRCA-associated breast cancer
Brigham and Women'S Hospital
FY2026$772,208R01CA307291
Congress activity
Updated 16 Oct 2026
277 congress contributions (2004–2025) across AACR, ASCO, ASH, ASTRO, ESMO, SABCS per OpenAlex. The most recent:
- Abstract 4004: Identification of predictive biomarkers of USP1 inhibitor sensitivity using ovarian cancer organoid models
AACR Annual Meeting
AACR2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 16 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Multicenter, Randomized, Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men With Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE).
Journal of clinical oncology
Clinical Trial2026 - Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial.
Nature medicine
Clinical Trial2026 - A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2.
Clinical cancer research
Clinical Trial2026 - Regulation of the immune CD155-CD226-TIGIT axis by cyclin D-CDK4/6.
Proceedings of the National Academy of Sciences of the United States of America
Article2026
Most-cited works
by citation count (OpenAlex)- 01Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer4,506 citations2010
- 02Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer1,997 citations2014
- 03KRAS <sup>G12C</sup> Inhibition with Sotorasib in Advanced Solid Tumors1,696 citations2020
- 04
- 05
Network
Updated 16 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 16 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/geoffrey-shapiro-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/geoffrey-shapiro-893a973
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/profile/Geoffrey-Shapiro
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - X / Twitter
x.com/GShapiroMDPhD
Mentions by others
where others cite or feature them- Facebook
facebook.com/AllianceForClinicalTrialsInOncology/posts/video-from-geoffrey-shapiro-md-phd-at-dana-farber-talks-about-the-courage-of-cli/1364401031938379
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com ↗ - Facebook
facebook.com/danafarbercancerinstitute/posts/geoffrey-shapiro-md-phd-who-leads-dana-farbers-early-drug-development-center-tal/10156378808037937
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com ↗ - LinkedIn
linkedin.com/posts/the-alliance-for-clinical-trials-in-oncology_video-from-geoffrey-shapiro-md-phd-activity-7369459441298993158-i6xD
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - Other
dana-farber.org/newsroom/unraveled-podcast
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - Other
iheart.com/podcast/269-oncology-for-the-inquisiti-110000554/episode/88-on-the-road-with-dr-149230644
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →iheart.com ↗ - X / Twitter
x.com/ALLIANCE_org/status/1963588105631322116
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 16 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- Board Certified
Medical Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - BA
Biochemistry, Columbia University
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →massachusettsasco.wildapricot.org ↗
Editorial & leadership roles
journal and society appointments- Institute Physician
Dana-Farber Cancer Institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - Editor
Clinical Cancer Research (AACR journal)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →aacrjournals.org ↗
Highly Cited Researcher
Clarivate's annual list, by award category and year- Clinical Medicine2019202020212022verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →massachusettsasco.wildapricot.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →massachusettsasco.wildapricot.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →massachusettsasco.wildapricot.org ↗
- George P. Canellos Award for Excellence in Clinical Investigation and Patient Care
Dana-Farber Cancer Institute
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →dana-farber.org ↗
Secondary affiliations
appointments beyond the home institution- Professor of Medicine
Harvard Medical School
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - Clinical Director
Center for DNA Damage and Repair, Dana-Farber Cancer Institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - Institute Physician
Dana-Farber Cancer Institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - Co-Leader
Developmental Therapeutics Research Program, Dana-Farber/Harvard Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dfhcc.harvard.edu ↗ - Member
Lung Cancer Research Program, Dana-Farber/Harvard Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dfhcc.harvard.edu ↗ - Scientific Advisory Board Member
Bicycle Therapeutics
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →biospace.com ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- "Putting the Spotlight on Rare Cancers"
Dana-Farber newsroom feature
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →dana-farber.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Kenneth Anderson, MD
Dana-Farber Cancer Institute
Paul Richardson, MD
Dana-Farber Cancer Institute
Toni Choueiri, MD
Dana-Farber Cancer Institute
Pasi Janne, MD, PhD
Dana-Farber Cancer Institute
Pasi Janne, MD, PhD
Dana-Farber Cancer Institute
Julie Brahmer, MD
Johns Hopkins University School of Medicine
Enriqueta Felip, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center